OncoResponse Raises $27M to Advance Antibody-Based Cancer Immunotherapies OR502 and OR2805

Seattle biotech firm OncoResponse secured $27 million to advance testing of its antibody-based cancer immunotherapy candidates OR502 and OR2805. The funding includes a $13 million grant from the Cancer Prevention and Research Institute of Texas and $14 million from investors led by RiverVest Venture Partners.